Abstract
Background/aimsSubretinal coapplication of recombinant tissue plasminogen activator (rtPA) and vascular endothelial growth factor (VEGF)-antagonists is a new treatment option for age-related macular degeneration complicated by submacular haemorrhage. Here, we investigate...
Highlights
Without treatment, the prognosis of neovascular age-related macular degeneration (AMD) complicated by submacular haemorrhage (SMH) is usually poor because the underlying choroidal neovascularisation (CNV) lesion progresses and the resolution of the haemorrhage is associated with the formation of a macular scar.[1]
While we have previously shown the compatibility of recombinant tissue plasminogen activator (rtPA) and bevacizumab in vitro,[15] it is unclear whether rtPA and ranibizumab or aflibercept are compatible
Interaction studies Recombinant tissue plasminogen activator We investigated the effect of rtPA on the band pattern of aflibercept and ranibizumab when applied in equal volumes, assessed in two different protein stains, and evaluating the molecular weight of the bands
Summary
The prognosis of neovascular age-related macular degeneration (AMD) complicated by submacular haemorrhage (SMH) is usually poor because the underlying choroidal neovascularisation (CNV) lesion progresses and the resolution of the haemorrhage is associated with the formation of a macular scar.[1]. Visual acuity often improved after successful displacement of SMH by recombinant tissue plasminogen activator (rtPA) and gas but frequently deteriorated because of progression of the underlying CNV. Since the advent of antivascular endothelial growth factor (anti-VEGF) pharmacotherapy, new aspects have been added to the management of neovascular AMD with SMH. Anti-VEGF agents delivered by intravitreal injection are a safe and effective treatment for neovascular AMD for up to 2 years.[6 7] In view of these clinical results, a combined intraocular application of rtPA and anti-VEGF agents could represent a significant improvement of current treatment concepts for AMD with SMH.[8,9,10,11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
